JP4763197B2 - 新規ワクチン - Google Patents

新規ワクチン Download PDF

Info

Publication number
JP4763197B2
JP4763197B2 JP2001524577A JP2001524577A JP4763197B2 JP 4763197 B2 JP4763197 B2 JP 4763197B2 JP 2001524577 A JP2001524577 A JP 2001524577A JP 2001524577 A JP2001524577 A JP 2001524577A JP 4763197 B2 JP4763197 B2 JP 4763197B2
Authority
JP
Japan
Prior art keywords
vaccine
dose
influenza
intranasal
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001524577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003509451A5 (enExample
JP2003509451A (ja
Inventor
フリード，マルタン
アンデリック，ベロニック
エルマン，フィリップ
モアム スラウイ，モンセフ
ガブリエル ジョゼフ トーラン，ステファン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922703.5A external-priority patent/GB9922703D0/en
Priority claimed from GBGB9922700.1A external-priority patent/GB9922700D0/en
Priority claimed from GB0016686A external-priority patent/GB0016686D0/en
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2003509451A publication Critical patent/JP2003509451A/ja
Publication of JP2003509451A5 publication Critical patent/JP2003509451A5/ja
Application granted granted Critical
Publication of JP4763197B2 publication Critical patent/JP4763197B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2001524577A 1999-09-24 2000-09-22 新規ワクチン Expired - Lifetime JP4763197B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GBGB9922700.1A GB9922700D0 (en) 1999-09-24 1999-09-24 Vaccine
GB9922703.5 1999-09-24
GB9922700.1 1999-09-24
GB0016686.8 2000-07-06
GB0016686A GB0016686D0 (en) 2000-07-06 2000-07-06 Novel vaccine
PCT/EP2000/009367 WO2001021151A1 (en) 1999-09-24 2000-09-22 Intranasal influenza virus vaccine

Publications (3)

Publication Number Publication Date
JP2003509451A JP2003509451A (ja) 2003-03-11
JP2003509451A5 JP2003509451A5 (enExample) 2007-09-06
JP4763197B2 true JP4763197B2 (ja) 2011-08-31

Family

ID=27255796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001524577A Expired - Lifetime JP4763197B2 (ja) 1999-09-24 2000-09-22 新規ワクチン

Country Status (23)

Country Link
US (2) US20050201946A1 (enExample)
EP (2) EP1214054B1 (enExample)
JP (1) JP4763197B2 (enExample)
KR (1) KR20020038771A (enExample)
CN (1) CN1391463A (enExample)
AR (2) AR032597A1 (enExample)
AT (1) ATE376825T1 (enExample)
AU (1) AU764368B2 (enExample)
BR (1) BR0014281A (enExample)
CA (1) CA2383105C (enExample)
CO (1) CO5280082A1 (enExample)
CZ (1) CZ20021044A3 (enExample)
DE (1) DE60036952T2 (enExample)
ES (1) ES2293923T3 (enExample)
HU (1) HUP0202846A3 (enExample)
IL (1) IL148673A0 (enExample)
MX (1) MXPA02003069A (enExample)
MY (1) MY126588A (enExample)
NO (1) NO20021431L (enExample)
NZ (1) NZ517903A (enExample)
PL (1) PL355287A1 (enExample)
TR (1) TR200200776T2 (enExample)
WO (1) WO2001021151A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
CA2438942A1 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
DK1909830T3 (da) * 2005-08-02 2011-12-19 Novartis Vaccines & Diagnostic Formindskelse af interferens mellem olieholdige adjuvanser og antigener indeholdende overfladeaktivt middel
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
HUE049580T2 (hu) 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
US20080038294A1 (en) * 2006-03-22 2008-02-14 Kersten Alexander J Intranasal or inhalational administration of virosomes
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
CN101015691B (zh) * 2006-11-14 2010-08-25 中国医学科学院医学生物学研究所 重组噬菌体流感疫苗
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
CN102046814B (zh) * 2008-06-02 2015-05-20 通用电气健康护理生物科学股份公司 浓度测定
WO2010052214A2 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
CU20080215A7 (es) 2008-11-19 2012-06-21 Inst Finlay Vacunas unitemporales
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
ES2394797T3 (es) 2009-05-21 2013-02-05 Novartis Ag Genética inversa usando promotores no endógenos de pol l
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP5716297B2 (ja) 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
JP5871806B2 (ja) 2009-10-20 2016-03-01 ノバルティス アーゲー ウイルスレスキューのための改善された逆遺伝学
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
RU2423995C1 (ru) * 2009-11-10 2011-07-20 Общество с ограниченной ответственностью "ФОРТ" Способ производства вакцины против гриппа
AU2011217903B2 (en) * 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
EP2566323A2 (en) 2010-05-06 2013-03-13 Novartis AG Organic peroxide compounds for microorganism inactivation
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
AU2011262309B2 (en) 2010-06-01 2015-08-13 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
CN101899101B (zh) * 2010-07-21 2012-07-25 中国检验检疫科学研究院 一种用于流感病毒亚单位疫苗研究的合成多肽
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
IN2014CN02114A (enExample) 2011-09-20 2015-05-29 Sinai School Medicine
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
HK1208502A1 (en) 2012-06-04 2016-03-04 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP2925356A2 (en) 2012-12-03 2015-10-07 Novartis AG Reassortant influenza a viren
UY34506A (es) * 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
AU2014204826A1 (en) 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
US10232031B2 (en) 2013-03-13 2019-03-19 Seqirus UK Limited Influenza virus reassortment
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014180999A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
BR112015030582A2 (pt) 2013-06-06 2017-08-29 Novartis Ag Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
EP3068791B1 (en) 2013-11-15 2020-07-29 Novartis AG Removal of residual cell culture impurities
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
CN105342982B (zh) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 经鼻给药的流感疫苗免疫制剂及其制备方法
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP7660514B2 (ja) * 2019-02-15 2025-04-11 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生インフルエンザワクチン組成物及びその調製プロセス
US20220168413A1 (en) 2019-02-25 2022-06-02 Seqirus UK Limited Adjuvanted multivalent influenza vaccines
AU2020380604A1 (en) 2019-11-07 2022-06-09 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size
MX2022006005A (es) 2019-11-18 2022-10-27 Seqirus Pty Ltd Metodo para producir virus de la influenza reagrupados.
CN113599513A (zh) * 2020-10-23 2021-11-05 青岛大学 一种适用于咽喉部接种的新型冠状病毒疫苗的制备方法及接种方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62281813A (ja) * 1986-04-23 1987-12-07 ファイゾンス・コーポレイション 鼻内投薬
JPH08506592A (ja) * 1993-02-19 1996-07-16 スミスクライン・ビーチャム・コーポレイション ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
JPH09508614A (ja) * 1993-02-15 1997-09-02 リュフヤトルン・エイチ・エフ 哺乳動物に対する抗原類および／またはワクチン類の粘膜を介した局所投与のための医薬調製物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627873A (en) * 1967-06-09 1971-12-14 Arden Wesley Moyer Influenza vaccine with reduced pyrogenicity
US3874381A (en) * 1974-05-28 1975-04-01 Smithkline Corp Dual nozzle intranasal delivery device
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5437267A (en) * 1993-08-03 1995-08-01 Weinstein; Allan Device for delivering aerosol to the nasal membranes and method of use
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
RU2086232C1 (ru) * 1994-06-03 1997-08-10 Уфимский научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Средство для интраназальной профилактики гриппа
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1999052549A1 (en) * 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6506803B1 (en) * 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
WO2001098206A1 (en) * 2000-06-22 2001-12-27 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
US20040096463A1 (en) * 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
CA2438942A1 (en) * 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62281813A (ja) * 1986-04-23 1987-12-07 ファイゾンス・コーポレイション 鼻内投薬
JPH09508614A (ja) * 1993-02-15 1997-09-02 リュフヤトルン・エイチ・エフ 哺乳動物に対する抗原類および／またはワクチン類の粘膜を介した局所投与のための医薬調製物
JPH08506592A (ja) * 1993-02-19 1996-07-16 スミスクライン・ビーチャム・コーポレイション ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物

Also Published As

Publication number Publication date
CA2383105A1 (en) 2001-03-29
ES2293923T3 (es) 2008-04-01
MY126588A (en) 2006-10-31
DE60036952T2 (de) 2008-08-07
IL148673A0 (en) 2002-09-12
EP1214054A1 (en) 2002-06-19
MXPA02003069A (es) 2002-09-30
AU7782500A (en) 2001-04-24
PL355287A1 (en) 2004-04-05
CN1391463A (zh) 2003-01-15
ATE376825T1 (de) 2007-11-15
TR200200776T2 (tr) 2002-06-21
HUP0202846A2 (hu) 2002-12-28
BR0014281A (pt) 2002-05-21
EP1878424A3 (en) 2008-04-09
DE60036952D1 (de) 2007-12-13
CZ20021044A3 (cs) 2002-08-14
WO2001021151A1 (en) 2001-03-29
JP2003509451A (ja) 2003-03-11
US20090155309A1 (en) 2009-06-18
HUP0202846A3 (en) 2003-12-29
KR20020038771A (ko) 2002-05-23
AU764368B2 (en) 2003-08-14
EP1878424A2 (en) 2008-01-16
NO20021431D0 (no) 2002-03-21
NZ517903A (en) 2003-10-31
CA2383105C (en) 2010-01-26
EP1214054B1 (en) 2007-10-31
NO20021431L (no) 2002-04-24
US20050201946A1 (en) 2005-09-15
AR032597A1 (es) 2003-11-19
AR025750A1 (es) 2002-12-11
CO5280082A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
JP4763197B2 (ja) 新規ワクチン
JP6211555B2 (ja) 新規なワクチン
JP2003509451A5 (enExample)
JP4074582B2 (ja) 新規なワクチン
JP2004536785A (ja) 新規なワクチン
AU2002344182A1 (en) Influenza vaccine composition
ZA200202269B (en) Intranasal influenza virus vaccine.
ES2361981T3 (es) Formulaciones de vacunas de la gripe para administración intradérmica.
HK1145984A (en) Influenza vaccine formulations for intradermal delivery
HK1147213A (en) Influenza vaccine formulations for intradermal delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110609

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140617

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4763197

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term